GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of anyone else notice SURPASS kicking in around week 19 — 23 comments in the full submission. View in context.
2.9k
c/trialwatch·submitted 1 year ago by u/marit_laurent

anyone else notice SURPASS kicking in around week 19

Readoutbranch of 4 comments

Genuinely asking, not being difficult. Everyone in c/compounding repeats that hazard ratio is important. I believe it, but I have never seen anyone show why, and when I search I get 12 threads of people agreeing with each other. Is there a paper? Is there a measurement? Or is this one of those things that is true…

Read the full submission and all 23 comments →

This branch

4 comments, started 1 year ago
u/renal_outcomes_rMOD159 points·1 year ago

Retitled to remove editorialising. Put the evidence in the body.

replysharereportpermalink
u/nhs_waitlist_nUK0 points·1 year ago

What was the dropout rate?

replysharereportpermalink
u/hugo_norgaard-31 points·1 year ago

Which trial and what was the primary endpoint?

replysharereportpermalink
u/marit_laurentOP1 point·1 year ago

SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →